SCHEMBL22411929

SCHEMBL22411929

CC(COCc1cc([N+](=O)[O-])c2cnn(C)c2c1)NC(=O)c1cnn2c(N(C)C(=O)OC(C)(C)C)cc(Cl)nc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31681403 1.00 — —
SCHEMBL22425795 0.90 — —
SCHEMBL29684175 0.90 — —
SCHEMBL22411868 0.86 P2RX3 (0.32) —
SCHEMBL22411869 0.86 P2RX3 (0.32) —
SCHEMBL24500844 0.82 CSNK1D (0.30) —
SCHEMBL29683954 0.81 ALDH1A1 (0.32) —
SCHEMBL22425986 0.81 CSNK1D (0.31) —
SCHEMBL22412064 0.81 CSNK1D (0.31) —
SCHEMBL22411825 0.80 LMNA (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177486-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2022-06-09 — — US disclosed
EP-3938369-A1 TYK2 INHIBITORS AND USES THEREOF Esker Therapeutics, Inc. (US) 2022-01-19 — — EP disclosed
WO-2020185755-A1 TYK2 INHIBITORS AND USES THEREOF FRONTHERA U.S. PHARMACEUTICALS LLC (US) 2020-09-17 — — WO disclosed
Send feedback